Tobacco consumption and premenstrual syndrome: A case-control study by Fernández, María del Mar et al.
RESEARCH ARTICLE
Tobacco consumption and premenstrual
syndrome: A case-control study
Marı́a del Mar Fernández1, Agustı́n Montes-Martı́nez1,2, Marı́a Piñeiro-Lamas1,2,
Carlos Regueira-Méndez1,2, Bahi TakkoucheID
1,2*
1 Department of Preventive Medicine, University of Santiago de Compostela, Santiago de Compostela,





To assess whether tobacco smoking is associated with Premenstrual Syndrome (PMS) and
its most severe form, Premenstrual Dysphoric Disorder (PMDD).
Design
Case-control study with incident cases using the Spanish public healthcare system.
Setting
3 major public hospitals and one family counseling and planning center.
Population
Women consulting for troubles related to menstruation and for other motives such as




Odds Ratios of PMS and PMDD.
Results
285 incident PMS cases and 285 age-matched controls on the one hand, and 88 incident
PMDD cases and 176 controls on the other hand participated in the study. The odds of pre-
menstrual disorders was higher in current smokers compared with never smokers: Odds
Ratio (OR) = 1.78, 95% Confidence Interval (CI): 1.20–2.63 for PMS and OR = 2.92, 95%CI:
1.55–5.50 for PMDD. For PMS, women who smoke 1 to 5 cigarettes/day presented an OR =
2.82, 95%CI: 1.57–5.06 and those who smoke more than 15 cigarettes/day an OR = 2.52,
95%CI: 0.99–6.40.
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Editor: Nülüfer Erbil, Ordu University, TURKEY
Received: December 27, 2018
Accepted: June 9, 2019
Published: June 21, 2019
Copyright: © 2019 Fernández et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The authors received no specific funding
for this work. The Department of Preventive
Medicine of the University of Santiago de
Compostela receives funding from the Regional
Ministry of Education, Universities and Vocational
Training (Consellerı́a de Educación, Universidades
y Formación Profesional), Santiago de Compostela,
Spain. (Grant ED431C 2018/20).
Compared to non-smokers, current and ex-smokers who smoked < 3 pack-years pre-
sented an OR = 1.79, 95%CI: 1.04–3.08 for PMS, and an OR = 3.06, 95%CI: 1.27–7.35 for
PMDD. Smokers of 3 to 8 pack-years presented an OR = 2.34, 95%CI: 1.33–4.13 for PMS
and OR = 3.56, 95%CI: 1.55–8.17 for PMDD.
These results were confirmed by the exposure-effect curve obtained from a cubic spline
model.
Conclusions
This study shows that smokers are more likely to develop PMS and PMDD.
Introduction
Premenstrual disorders are defined as the set of recurrent physical and psychic symptoms in
the luteal phase of the menstrual cycle. Within these disorders, two main categories are to be
highlighted: premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD), a
more severe form [1]. Both clinical presentations have a common pathophysiological basis,
although they are classified separately [2].
The prevalence sways between 20 and 40% for PMS and between 3 and 8% for PMDD in
women of childbearing age in the United States [3], while a meta-analysis found that PMS
affects about half of the female population worldwide, with the lowest prevalence in Switzer-
land (10%) and the highest in Iran (98%) [4].
The PMS symptoms affect normal daily activities, and interfere with work, studies, and
interpersonal relationships [3,5]. Women who suffer from these symptoms have a 9-fold
increased risk of reporting one week a month of malaise, with most of the consequences
described above [3].
An American study estimated the annual costs of PMS at $ 5000 per woman per year [3]. It
is remarkable that a large proportion of the cases is not diagnosed, as women do not consult a
physician for the symptoms and sometimes because physicians have difficulties in establishing
a diagnosis of PMS [6], or because they consider it a mere cultural and social construct and
not a real disease [7]. As a consequence, the burden of women seeking medical help and
receiving a diagnosis is small and is probably declining [8].
Tobacco affects the regulation of sex hormones such as estrogens, progesterone and andro-
gens as well as the regulation of gonadotropic hormones and previous studies have linked sex
hormones to the pathophysiology of PMS [9]. In particular, it was observed that the intensity
of premenstrual symptoms augments proportionally to the increase in the concentrations of
estrogen and progesterone in the luteal phase [10].
The World Health Organization considers tobacco consumption among women as an epi-
demic. Tobacco smoking has very serious consequences for the health of the woman, the fetus
and the neonate as a passive smoker [11]. A report of the Surgeon General suggests that smok-
ing can alter the menstrual function by increasing the risk of dysmenorrhea, amenorrhea and
irregular menstruation [12]. All these problems cause a dramatic increase in the costs for
health systems, and lead to a worse health for women and their families [11]. Furthermore, the
World Health Organization calls for further studies on tobacco smoking in relation to aspects
of menstruation [11]. Except for African countries in which female smoking prevalence is low,
about one-fifth of women in Europe and America are current smokers. About 17% of women
are smokers in the US, 24% in Spain and 20% in the UK [11].
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The scarce studies that are available on the topic suggest that tobacco consumption is more
common in women with PMS or PMDD [13–16]. However, it is not clear whether tobacco is a
cause or a consequence of these syndromes as, with the exception of a prospective study [17],
the studies are of cross-sectional nature.
The objective of our study is, therefore, to investigate to what extent tobacco smoking is
related to the occurrence of premenstrual syndrome.
Methods
Study population
We set up a case-control study with newly diagnosed cases of PMS and PMDD. We selected
285 cases of PMS among women consulting for troubles related to menstruation and 285 con-
trols. We also selected 88 cases of PMDD and 176 individually controls. Cases and controls
were selected from 3 major public hospitals and one family counseling and planning center in
the city of Santiago de Compostela, which attend a population of 400,000 users. Controls were
individually age-matched to cases in each center.
The study was authorized by the regional Ethics Committee. All participants signed a con-
sent form.
Data collection
Data were collected through a voluntary, anonymous and self-completed questionnaire.
Potential cases and controls were selected by the health personnel (gynecologist, midwife) in
charge of the consultation.
To determine cases, we used the Premenstrual Syndrome Screening Tool (PSST) [18]. This
questionnaire consists of 19 questions about physical, behavioral and psychological symptoms
in the 5 days before the menstruation of the last three months. The severity of each symptom is
graded from 1 to 4 (1: none, 4: very intense). Symptoms such as irritability and nervousness
have a higher weight than physical symptoms. This, together with the higher or lower score
obtained, allows to differentiate between PMS and PMDD.
To define a PMS or PMDD case, the following algorithm was used. First, for PMS, a
score� 3 was needed in one of the 4 questions about whether the woman felt "irritable,"
"tense," "tearful," or "depressed". A score of 4 in one of these questions was necessary to define
a case of PMDD. In addition, to define a case of PMS, a score� 3 was required in one of the 5
variables of interference with "work performance, relationship with colleagues, family mem-
bers, in social life or in household tasks". A score of 4 was necessary to define a case of PMDD.
The last condition was to present a score� 3 in at least 4 of the first 14 questions (that is, all
questions except the 5 questions related to interference) for both PMS and PMDD. Both case
definitions follow the guidelines proposed in the PSST. When a patient fulfilled the case defini-
tion, we proceeded to assess exposure as explained below. Patients that did not meet the
requirements were excluded from the study.
Controls were selected from women who attended the same consultation for motives other
than PMS such as screening for uterine cancer, contraception counselling or desire for preg-
nancy. Absence of PMS was confirmed using the same questionnaire as above. In order to be
included as controls, women had to present a score� 2 on each of the 4 variables that describe
whether they felt "irritable", "tense", "tearful" or "depressed" and also a score� 2 on all variables
of interference which were described earlier. After being included as a control, tobacco expo-
sure was assessed as we did for the cases. Women who did not meet case or control definitions
were excluded from the study.
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The exposure questionnaire consisted of a series of items about tobacco smoking habits as
well as symptoms related to menstruation, socio-demographic factors, constitutional factors,
and other lifestyle factors that could possibly be confounders of the relationship between PMS
and tobacco. A food frequency questionnaire was also used to determine usual intake of macro
and micronutrients [19]. To assess tobacco consumption, we used the questionnaire of the
World Health Organization [20]. For this purpose, we created 4 variables: 1) smoking status,
with the categories "never smoker", "current smoker" and "ex-smoker", 2) quantity of pack-
years of tobacco smoked by smokers and ex-smokers, 3) time since quitting for ex-smokers,
and 4) number of units consumed per day in current smokers.
Statistical analysis
We used unconditional logistic regression to obtain crude and adjusted odds ratios along with
their 95% confidence intervals. This method was preferred to the conditional logistic regres-
sion to increase precision in the estimates without any loss of validity [21]. We conducted
independent analyses for PMS and PMDD.
Those covariates that changed the estimate of the OR of tobacco consumption by more
than 10% were introduced in the final model [22]. This model included the following variables:
age, previous pregnancies, age of menarche, Body Mass Index (BMI) and educational level.
The following covariates were considered for their possible inclusion in the model as con-
founders, but were eventually ruled out due to their lack of effect: health center, menstrual
regularity, history of abortions, use of oral contraception, use of intrauterine device and anti-
depressant treatment. The following candidate variables were also discarded from the final
model for the same reason: alcohol consumption, physical activity, intake of various nutrients
(calcium, caffeine, histamine, tyramine, omega 3 and 6 fatty acids, beta-carotene, lutein, pro-
tein, total fat, saturated fatty acids, monounsaturated fatty acids, cholesterol, carbohydrates,
fiber, sodium, potassium, magnesium, manganese, phosphorus, iron, copper, zinc, chlorine,
selenium, iodine, vitamins, nitrates, nitrites, amino acids and total consumption of kilocalo-
ries). The analyses were performed with STATA, version 12.
To explore the shape of the curve that relates tobacco consumption to the occurrence of epi-
sodes of PMS and PMDD, we fitted a model with cubic splines adjusted for potential factors of
confounding. We set 3 knots in the limits of exposure categories (0, 0.1–2.9, 3–7.9 and� 8
pack-years). The number of knots as well as the type of cubic spline regression were deter-
mined using the Bayesian Information Criterion (BIC).
Results
285 cases with PMS and 285 controls (case-control ratio 1:1), as well as 88 cases with PMDD
and their corresponding 176 controls (case-control ratio 1:2) participated in this study. The
response rate was 80% in cases and 80% in controls. The average age was 32 years for cases and
controls, both for PMS and PMDD. Due to the low number of partial missing data, and thus,
the fact that these missing data could not sensibly modify the results, we did not perform any
imputation procedure. Subjects with partial missing data were not included in the analysis.
In Table 1 we observe that PMS cases had an earlier menarche and a lower body mass index
than controls, as well as a higher proportion of nulliparous women. Likewise, we observe that
a high proportion of the sample has a university level of education, due to the fact that the city
in which this study was carried out is a university city. This proportion is higher in cases of
PMS than in controls. In Table 2, we observe that the distribution of the variables among
PMDD cases and their controls is very similar to that observed for PMS cases and their
controls.
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Table 1. Distribution of 285 premenstrual syndrome cases and 285 age-matched controls according to social, anthropometric and gynecological variables.
Characteristics Category N˚ cases % N˚ controls %
Body mass index (Kg/m2)� <19 22 8.1 14 5.2
19–24.9 182 67.4 160 59.9
25–30 41 15.2 62 23.2
>30 25 9.3 31 11.6
Educational level� Primary 46 16.3 46 16.1
Secondary 80 28.4 111 38.9
University 156 55.3 128 44.9
Menarche age� < = 11 74 26.1 48 16.8
12 y 13 153 54.1 162 56.8
> = 14 56 19.8 75 26.3
Number of pregnancies 0 147 51.6 131 46.0
1 66 23.2 70 24.6
> 1 72 25.3 84 29.5
Number of abortions 0 233 81.8 229 80.4
1 43 15.1 49 17.2
> 1 9 3.2 7 2.5
Oral contraception� No 181 80.8 187 81.0
Yes 43 19.2 44 19.0
Intrauterine device� No 235 92.9 240 91.3
Yes 18 7.1 23 8.7
�The sum of different categories is < total number of cases or controls due to partial missing data
https://doi.org/10.1371/journal.pone.0218794.t001
Table 2. Distribution of 88 premenstrual dysphoric disorder cases and 176 age-matched controls according to social, anthropometric and gynecological variables.
Characteristics Category N˚ cases % N˚ controls %
Body mass index (Kg/m2)� <19 8 9.6 9 5.4
19–24.9 56 67.5 108 65.1
25–30 14 16.9 35 21.1
>30 5 6.0 14 8.4
Educational level� Primary 18 20.9 31 17.6
Secondary 23 26.7 72 40.9
University 45 52.3 73 41.5
Menarche age < = 11 21 23.9 27 15.3
12 y 13 50 56.8 98 55.7
> = 14 17 19.3 51 29.0
Number of pregnancies 0 47 53.4 74 42.0
1 18 20.5 48 27.3
> 1 23 26.1 54 30.7
Number of abortions 0 69 78.4 147 83.5
1 13 14.8 24 13.6
> 1 6 6.8 5 2.8
Oral contraception� no 57 80.3 112 80.0
yes 14 19.7 28 20.0
Intrauterine device� no 72 93.5 147 93.0
yes 5 6.5 11 7.0
�The sum of different categories is < total number of cases or controls due to partial missing data
https://doi.org/10.1371/journal.pone.0218794.t002
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Effect of tobacco consumption on PMS
The association of PMDD with tobacco is shown in Table 3. Current tobacco consumption
was associated with increased occurrence of PMS (OR = 1.78, 95% CI: 1.20–2.63). Ex-smokers
are also twice more likely than non-smokers to present PMS, although the confidence interval
of the association is wider than for current smoking due to the small sample size of this expo-
sure group (OR = 1.98, 95% CI: 0.92–4.23).
Compared to non-smokers, current and ex-smokers whose total quantity of pack-years
consumed was less than 3 pack-years were more likely to develop PMS (OR = 1.79, 95% CI:
1.04–3.08). For those who smoked 3 to 8 pack-years the OR was 2.34 (95%CI: 1.33–4.13). The
spline curve (Fig 1) shows an increase in the odds of PMS for a tobacco consumption of less
than 10 pack-years. The odds decreases for a consumption of 10 to 25 pack-years but shows an
exponential increase for higher consumptions, albeit with imprecise estimates due to the small
sample size, as shown by the amplitude of the confidence interval.
As for daily consumption, women who smoke between 1 and 5 cigarettes/day and those
who smoke more than 15 cigarettes/day are more likely to suffer from PMS than non-smokers
(OR = 2.82, 95%CI: 1.57–5.06 and OR = 2.52, 95% CI: 0.99–6.40, respectively).
Due to the low number of ex-smokers in our sample, the analysis of the time elapsed since
quitting their addiction in relation to PMS yielded results with confidence intervals that were
too wide to draw reliable conclusions.
Effect of tobacco consumption on PMDD
The association of PMDD with tobacco is shown in Table 4. As in PMS, current smoking is
related to PMDD (OR = 2.92, 95% CI: 1.55–5.50). Furthermore, women who had smoked less
than 3 pack-years (OR = 3.06, 95%CI: 1.27–7.35) and those who had smoked between 3 and 8
pack-years (OR = 3.56, 95%CI: 1.55–8.17) were also more likely to develop PMDD than non-
smokers. As in the analysis of PMS, the effect observed in smokers of 8 and more pack-years is
lower and its confidence interval is imprecise.
Table 3. Crude and adjusted odds ratios (OR) of tobacco consumption and premenstrual syndrome.
Characteristics Category N˚ cases % N˚ controls % Crude OR 95% CI Adjusted OR� 95% CI
Smoking status never 138 51.3 171 62.2 1.00 1.00
current 111 41.3 88 32.0 1.56 1.09–2.24 1.78 1.20–2.63
ex-smoker 20 7.4 16 5.8 1.66 0.82–3.40 1.98 0.92–4.23
Cigarettes / day 0 138 56.6 171 67.1 1.00 1.00
1–5 51 20.9 22 8.6 2.87 1.66–4.97 2.82 1.57–5.06
6–15 41 16.8 53 20.8 0.96 0.60–1.52 1.12 0.68–1.85
> 15 14 5.7 9 3.5 1.93 0.81–4.59 2.52 0.99–6.40
Pack-years Never smoker 138 52.7 171 63.6 1.00 1.00
0.1–2.9 43 16.4 35 13.0 1.54 0.93–2.55 1.79 1.04–3.08
3.0–7.9 48 18.3 27 10.0 2.21 1.31–3.72 2.34 1.33–4.13
� 8.0 33 12.6 36 13.4 1.11 0.65–1.03 1.29 0.73–2.30
Time without smoking (years) Never smoker 138 87.3 171 91.9 1.00 1.00
1–3 5 3.2 6 3.2 1.02 0.31–3.43 1.14 0.33–3.96
3.1–8 7 4.4 4 2.2 2.12 0.60–7.43 2.35 0.56–9.92
> 8 8 5.1 5 2.7 1.90 0.60–6.07 2.24 0.69–7.33
� Adjusted for age, previous pregnancies, menarche age, Body Mass Index and educational level.
https://doi.org/10.1371/journal.pone.0218794.t003
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Fig 1. Adjusted odds ratios of PMS and PMDD, calculated by cubic spline regression according to pack-years of tobacco from a case-
control study. Continuous line: point estimates; dotted lines: 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0218794.g001
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The spline curve that relates exposure to tobacco to occurrence of PMDD (Fig 1) presents a
very similar form to that relating tobacco and PMS, with a significant increase in the odds for
low consumption and imprecise estimates for higher consumptions.
As for the number of cigarettes consumed per day, we observed that light and moderate
smokers are related to the occurrence of PMDD. Heavy smokers present a relation of similar
magnitude, albeit with a wider confidence interval.
The diagnosis of PMS and PMDD is based essentially on the evaluation of variables related
to mood. These variables could overlap with factors that are related to psychological stress. In
order to rule out any effect due to stress, we carried out a second analysis restricted to those
participants who presented a low level of perceived stress (156 subjects for PMS analysis and
81 subjects for PMDD analysis), measured by the scale proposed by Cohen et al. [23]. After
restriction, the results still showed a strong relation of tobacco smoking with PMS and PMDD:
OR for current smokers 3.21 (95% CI: 1.28–8.03) for PMS and 8.55 (95% CI: 1.55–47.03) for
PMDD.
Discussion
Our results suggest that women who smoke are more likely to suffer from both PMS and
PMDD. The fact that they have ever smoked increases the odds of suffering both forms of the
syndrome. Current smoking is clearly associated with increased PMS/PMDD. However,
although the effect persists in women who quit smoking, the association observed is imprecise
due to the reduced number of ex-smokers in our study.
Our results are in accordance with the only prospective study carried out so far on the rela-
tion between smoking and the development of PMS [17]. The magnitude of the effect is similar
in both studies. However, that study showed a dose-response effect of tobacco and PMS, some-
thing our study did not reveal, possibly due to differences in consumption categories between
the two studies. Furthermore, our results are also consistent with results of other cross-sec-
tional studies, although it should be highlighted that these are more prone to reverse causality
bias that might explain their findings [13–15, 24, 25].
Table 4. Crude and adjusted odds ratios (OR) of tobacco consumption and premenstrual dysphoric disorder.
Characteristics Category N˚ cases % N˚ controls % Crude OR 95% CI Adjusted OR� 95% CI
Smoking status never 37 43 106 62.4 1.00 1.00
current 43 50.0 54 31.8 2.28 1.31–3.98 2.92 1.55–5.50
ex-smoker 6 7.0 10 5.9 1.73 0.58–5.20 1.70 0.52–5.57
Cigarettes / day 0 37 16.8 106 67.5 1.00 1.00
1–5 19 24.1 12 7.6 4.56 2.02–10.31 4.53 1.82–11.24
6–15 20 25.3 35 22.3 1.63 0.84–3.17 2.19 1.03–4.65
> 15 3 3.8 4 2.5 2.18 0.46–10.21 3.87 0.70–21.34
Pack-years Never smoker 37 44.1 106 63.9 1.00 1.00
0.1–2.9 17 20.2 18 10.8 2.78 1.28–6.05 3.06 1.27–7.35
3.0–7.9 20 23.8 20 12.1 2.86 1.39–5.90 3.56 1.55–8.17
� 8.0 10 11.9 22 13.3 1.25 0.52–2.97 1.62 0.64–4.12
Time without smoking (years) Never smoker 37 86.0 106 91.4 1.00 1.00
1–3 1 2.3 4 3.4 0.72 0.78–6.71 0.67 0.57–7.87
3.1–8 3 7.0 3 2.6 2.60 0.49–13.76 1.59 0.26–9.79
>8 2 4.7 3 2.6 1.58 2.35–10.58 2.11 0.29–15.39
� Adjusted for age, previous pregnancies, menarche age, Body Mass Index and educational level.
https://doi.org/10.1371/journal.pone.0218794.t004
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It has been shown that tobacco decreases the activity of monoamine oxidase (MAO), an
enzyme that degrades serotonin, a neurotransmitter involved in the pathophysiology of PMS
[26]. This inhibition seems to be related to the amount of tobacco and the time of consump-
tion [26]. During smoking, MAO is strongly inhibited, but its synthesis is increased consider-
ably in order to compensate for this inhibition [26]. It is then plausible that quitting from
smoking may increase serotonin degradation. This could then explain the increasing probabil-
ity of developing PMS and PMDD as abstinence time augments.
Previous reports favor the hypothesis of a relationship between dysmenorrhea and PMS
[27]. It is likely that estrogens exert an effect on both PMS and dysmenorrhea [10, 28]. In our
study, additional adjustment for the presence of dysmenorrhea decreased the magnitude of the
relation between tobacco and PMS (data not shown). In view of the association of PMS and
dysmenorrhea, it is probable that dysmenorrhea could play the role of an intermediate variable
in the causal path between tobacco and PMS. Adjusting for the variable “dysmenorrhea”
would then cause an overadjustment and, therefore, would introduce additional bias in the
assessment of the relation between tobacco and PMS [29].
As in any case-control study, our study may be subject to recall bias. In theory, PMS cases
may better remember their tobacco intake than controls. However, this is unlikely to occur, as,
in general, smoking is a stable habit throughout life [30]. Also, different studies have mani-
fested that self-reporting of tobacco consumption is a valid method for measuring tobacco
exposure when compared to biological measures such as measurement of cotinine or carbon
monoxide [31]. In addition, our diagnosis of PMS was not openly revealed to the participants,
since it consisted of a score that originated from several independent questions. The hypothe-
sis of the study, i.e. the relation between tobacco intake and premenstrual syndrome, was not
disclosed to the participants, since tobacco smoking was only one among several exposure fac-
tors that have been assessed in the exposure questionnaire.
We cannot rule out a certain amount of misclassification in the PMS/PMDD assessment
since the diagnosis is based on a subjective symptom score. However, this misclassification
bias, if any, is unlikely to modify the conclusion of this study, first because the screening tool
used to diagnose PMS was previously validated; although not in our population but in a similar
one [32]. Second, because if there is any erroneous classification, it is likely that this error
occurs regardless of the exposure status, since the subjects were not aware of the hypothesis of
the study that related smoking and PMS.
To explore the direction and magnitude of the potential bias due to misclassification of out-
come, we reanalyzed the data by introducing the variable "smoking" as dichotomous, first as
ever smoker/never smoker and then as current smoker/current non-smoker. The resulting
odds ratios were for PMS 1.56, 95% CI: 1.11–2.20) and 1.49, 95% CI: 1.05–2.12) respectively,
and for PMDD 2.19, 95% CI: 1.29–3.72) and 2.15, 95% CI: 1.26–3.66). These results, suggest
that the true association between smoking and PMS may even be stronger than the one we
have observed, as non-differential misclassification of a dichotomous variable yield bias
towards the null value, that is, decreases the effect [33].
Some of our findings are limited by the small sample size in some categories of exposure.
This had lead to estimates with wide confidence intervals. Also, generalizability of the findings
may be a concern due to the fact that the study was carried out among women with high edu-
cation level.
Conclusion
In this study we observed that smoking is related to both PMS and PMDD. Future research
should determine how long it takes to eliminate the effect of tobacco on PMS and PMDD after
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quitting. Also, it would be of interest to determine whether smoking may have an in utero
effect, increasing the risk of PMS in women whose mothers smoked during pregnancy. As for
any etiologic research, cross-sectional designs are best avoided.
The World Health Organization expects an increase in tobacco consumption among
women in emerging countries, which are the most densely populated and those which harbor
the highest birth rates [11]. Tobacco harm is personal, environmental and transgenerational.
Given the very large number of women currently concerned by the syndrome and in anticipa-
tion of future affectation, it is important to decide whether health authorities should warn
against the risk that tobacco consumption induces in the development of PMS / PMDD.
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